Subscribe
scientist-istock-505918900
gevende / iStockphoto.com
6 February 2019Americas

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion ($3.3 billion) immunotherapy deal with Germany-based Merck KGaA.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More on this story

Asia-Pacific
Merck KGaA secures CRISPR patent in China
26 April 2018   China’s State Intellectual Property Office has granted Merck KGaA a patent covering its CRISPR technology used in a genomic-integration method for eukaryotic cells.
Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent